A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 141
- Registration Number
- NCT06598371
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Extending Outcomes for Pancreas Cancer Patients with Nominal Oligometastatic Disease (EXPAND): a Randomized Phase III Trial
Phase 3
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-09-12
- Last Posted Date
- 2024-09-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT06593431
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Quantitative Imaging Biomarker Prospective Validation of Dynamic Contrast-enhanced MRI As a Metric of Orodental Injury After Radiotherapy (QI-ProVE-MRI)
Not yet recruiting
- Conditions
- First Posted Date
- 2024-09-06
- Last Posted Date
- 2024-09-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 300
- Registration Number
- NCT06586892
Feasibility of the Use of Weighted Blankets to Improve Sleep Among Patients with Hematological Malignancies
Not Applicable
Not yet recruiting
- Conditions
- First Posted Date
- 2024-09-05
- Last Posted Date
- 2024-09-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06584955
Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study
- First Posted Date
- 2024-09-04
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 110
- Registration Number
- NCT06584396
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Open Label Single Arm Pilot Trial of Letermovir for Cytomegalovirus Prophylaxis After Axicabtagene Ciloleucel Therapy
Not Applicable
Not yet recruiting
- Conditions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT06575374
Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-28
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 128
- Registration Number
- NCT06576037
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase II Trial Utilizing Metronidazole to Optimize the Microbiome of Rectal Adenocarcinoma Undergoing Neoadjuvant Therapy
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06569368
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 15
- Registration Number
- NCT06566742
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Study of Ivonescimab in Patients With Cutaneous Squamous Cell Carcinoma
- First Posted Date
- 2024-08-22
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT06567314
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath